ICCM
アイスキュア・メディカル
ICCM
アイスキュア・メディカル
Agreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the
Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer